{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T15:40:04Z","timestamp":1748792404731,"version":"3.41.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-00978-3","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T09:09:43Z","timestamp":1740992983000},"page":"442-449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early administration of caplacizumab combined with plasma exchange for thrombotic microangiopathy due to malignant hypertension: a case report"],"prefix":"10.1007","volume":"14","author":[{"given":"Hiroyuki","family":"Okawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-8735","authenticated-orcid":false,"given":"Yukihiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Uchitsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayumi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Sakurabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shokichi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Togo","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"5","key":"978_CR1","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.kint.2024.02.014","volume":"105","author":"V Maisons","year":"2024","unstructured":"Maisons V, Duval A, Mesnard L, Frimat M, Fakhouri F, Grang\u00e9 S, et al. Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies. Kidney Int. 2024;105(5):1100\u201312.","journal-title":"Kidney Int"},{"issue":"7","key":"978_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654\u201366.","journal-title":"N Engl J Med"},{"issue":"2","key":"978_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312\u201322.","journal-title":"J Thromb Haemost"},{"issue":"10095","key":"978_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681\u201396.","journal-title":"Lancet"},{"key":"978_CR5","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","volume":"3","author":"JA Kremer Hovinga","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, L\u00e4mmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3:17020.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"978_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2215\/CJN.0000000000000182","volume":"18","author":"A Werion","year":"2023","unstructured":"Werion A, Storms P, Zizi Y, Beguin C, Bernards J, Cambier JF, et al. Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies. Clin J Am Soc Nephrol. 2023;18(7):881\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"978_CR7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/bjh.18577","volume":"201","author":"J Schofield","year":"2023","unstructured":"Schofield J, Hosseinzadeh S, Burton K, Pavord S, Dutt T, Doree C, et al. Drug-induced thrombotic thrombocytopenic purpura: a systematic review and review of European and North American pharmacovigilance data. Br J Haematol. 2023;201(4):766\u201373.","journal-title":"Br J Haematol"},{"issue":"5","key":"978_CR8","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/bjh.19284","volume":"204","author":"RR Schimmer","year":"2024","unstructured":"Schimmer RR, Sutter T, Bachofner A, Ranieri E, Rodewald AK, Kremer Hovinga JA, et al. Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab. Br J Haematol. 2024;204(5):1994\u20138.","journal-title":"Br J Haematol"},{"issue":"5","key":"978_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","volume":"81","author":"DS Genest","year":"2023","unstructured":"Genest DS, Patriquin CJ, Licht C, John R, Reich HN. Renal thrombotic microangiopathy: a review. Am J Kidney Dis. 2023;81(5):591\u2013605.","journal-title":"Am J Kidney Dis"},{"key":"978_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev.med.53.082901.103948","volume":"53","author":"JL Moake","year":"2002","unstructured":"Moake JL. Thrombotic thrombocytopenic purpura: the systemic clumping \u201cplague.\u201d Annu Rev Med. 2002;53:75\u201388.","journal-title":"Annu Rev Med"},{"issue":"22","key":"978_CR11","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578\u201384.","journal-title":"N Engl J Med"},{"issue":"22","key":"978_CR12","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","volume":"339","author":"HM Tsai","year":"1998","unstructured":"Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585\u201394.","journal-title":"N Engl J Med"},{"issue":"19","key":"978_CR13","first-page":"1847","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(19):1847\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"978_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/ndt\/gfac248","volume":"38","author":"T Cavero","year":"2023","unstructured":"Cavero T, Au\u00f1\u00f3n P, Caravaca-Font\u00e1n F, Trujillo H, Arjona E, Morales E, et al. Thrombotic microangiopathy in patients with malignant hypertension. Nephrol Dial Transplant. 2023;38(5):1217\u201326.","journal-title":"Nephrol Dial Transplant"},{"key":"978_CR15","doi-asserted-by":"crossref","unstructured":"He F, Zhou Z, Zhao S, Li W, Lian X, Yu J, et al. Impact of Overweight on Renal Prognosis in Malignant Hypertension Patients With Thrombotic Microangiopathy. J Clin Lab Anal. 2024:e25118.","DOI":"10.1002\/jcla.25118"},{"key":"978_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-024-00933-8","author":"N Iwamura","year":"2024","unstructured":"Iwamura N, Matsukuma Y, Katafuchi E, Nakano Y, Tsutsumi K, Ueno Y, et al. Managing malignant hypertension with renal TMA: a case for caution in blood-pressure reduction. CEN Case Rep. 2024. https:\/\/doi.org\/10.1007\/s13730-024-00933-8.","journal-title":"CEN Case Rep"},{"issue":"11","key":"978_CR17","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1097\/01.hjh.0000249710.21146.38","volume":"24","author":"BJ van den Born","year":"2006","unstructured":"van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006;24(11):2299\u2013304.","journal-title":"J Hypertens"},{"issue":"2","key":"978_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/10641963.2010.503303","volume":"33","author":"T Akimoto","year":"2011","unstructured":"Akimoto T, Muto S, Ito C, Takahashi H, Takeda S, Ando Y, et al. Clinical features of malignant hypertension with thrombotic microangiopathy. Clin Exp Hypertens. 2011;33(2):77\u201383.","journal-title":"Clin Exp Hypertens"},{"issue":"3","key":"978_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1291\/hypres.31.479","volume":"31","author":"B Zhang","year":"2008","unstructured":"Zhang B, Xing C, Yu X, Sun B, Zhao X, Qian J. Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res. 2008;31(3):479\u201383.","journal-title":"Hypertens Res"},{"issue":"2","key":"978_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","volume":"45","author":"BJ van den Born","year":"2005","unstructured":"van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005;45(2):246\u201351.","journal-title":"Hypertension"},{"issue":"4","key":"978_CR21","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1161\/HYPERTENSIONAHA.107.103127","volume":"51","author":"BJ van den Born","year":"2008","unstructured":"van den Born BJ, van der Hoeven NV, Groot E, Lenting PJ, Meijers JC, Levi M, et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension. 2008;51(4):862\u20136.","journal-title":"Hypertension"},{"issue":"2","key":"978_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","volume":"37","author":"S Rubin","year":"2019","unstructured":"Rubin S, Cremer A, Boulestreau R, Rigothier C, Kuntz S, Gosse P. Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. J Hypertens. 2019;37(2):316\u201324.","journal-title":"J Hypertens"},{"issue":"6","key":"978_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Kn\u00f6bl P, Wu H, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"978_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Kn\u00f6bl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335\u201346.","journal-title":"N Engl J Med"},{"issue":"9","key":"978_CR25","first-page":"1124","volume":"64","author":"M Matsumoto","year":"2023","unstructured":"Matsumoto M. Novel treatment strategies for acquired thrombotic thrombocytopenic purpura. Rinsho Ketsueki. 2023;64(9):1124\u201330.","journal-title":"Rinsho Ketsueki"},{"issue":"5","key":"978_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s12185-023-03657-0","volume":"118","author":"M Matsumoto","year":"2023","unstructured":"Matsumoto M, Miyakawa Y, Kokame K, Ueda Y, Wada H, Higasa S, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol. 2023;118(5):529\u201346.","journal-title":"Int J Hematol"},{"key":"978_CR27","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Corral P, Gonz\u00e1lez-Rubio C, Rodr\u00edguez de C\u00f3rdoba S, L\u00f3pez-Trascasa M. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol. 2004;41(1):81\u20134.","DOI":"10.1016\/j.molimm.2004.01.003"},{"issue":"5","key":"978_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124655","volume":"10","author":"Y Yoshida","year":"2015","unstructured":"Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, et al. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS ONE. 2015;10(5): e0124655.","journal-title":"PLoS ONE"},{"issue":"4","key":"978_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010208","volume":"5","author":"P Coppo","year":"2010","unstructured":"Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE. 2010;5(4): e10208.","journal-title":"PLoS ONE"},{"issue":"4","key":"978_CR30","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","volume":"4","author":"PK Bendapudi","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157\u201364.","journal-title":"Lancet Haematol"},{"key":"978_CR31","doi-asserted-by":"crossref","unstructured":"Grall M, Azoulay E, Galicier L, Prov\u00f4t F, Wynckel A, Poullin P, et al. Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. Am J Hematol. 2017;92(4):381\u20137.","DOI":"10.1002\/ajh.24665"},{"issue":"2","key":"978_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1751-553X.2006.00829.x","volume":"29","author":"JF Lesesve","year":"2007","unstructured":"Lesesve JF, Salignac S, Lecompte T. Laboratory measurement of schistocytes. Int J Lab Hematol. 2007;29(2):149\u201351.","journal-title":"Int J Lab Hematol"},{"key":"978_CR33","doi-asserted-by":"crossref","unstructured":"Sethi SK, S S, Nair A, Soni K, Bihari Bansal S, Rana AS, et al. What came first, atypical hemolytic uremic syndrome or malignant hypertension: a clinical dilemma. Ren Fail. 2024;46(1):2327484.","DOI":"10.1080\/0886022X.2024.2327484"},{"issue":"6","key":"978_CR34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","volume":"137","author":"P Coppo","year":"2021","unstructured":"Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Big\u00e9 N, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733\u201342.","journal-title":"Blood"},{"issue":"7","key":"978_CR35","volume":"14","author":"S Mandyam","year":"2022","unstructured":"Mandyam S, Fatmi SS, Banzon G, Kaur P, Katamreddy Y, Parghi D, et al. A rare case of severe manifestation of COVID-19 infection presenting as immune-related thrombotic thrombocytopenic purpura with multiorgan involvement treated with plasmapheresis, steroids, rituximab, and caplacizumab. Cureus. 2022;14(7): e26961.","journal-title":"Cureus"},{"issue":"1","key":"978_CR36","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.1038\/s41598-023-33007-3","volume":"13","author":"NA Turner","year":"2023","unstructured":"Turner NA, Moake JL. Heat-inactivated Factor B inhibits alternative pathway fluid-phase activation and convertase formation on endothelial cell-secreted ultra-large von Willebrand factor strings. Sci Rep. 2023;13(1):5764.","journal-title":"Sci Rep"},{"issue":"1","key":"978_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/HJH.0000000000003316","volume":"41","author":"Z Yu","year":"2023","unstructured":"Yu Z, Liu Y, Zhang Y, Cui J, Dong Y, Zhang L, et al. Ulinastatin ameliorates preeclampsia induced by N(gamma)-nitro-l-arginine methyl ester in a rat model via inhibition of the systemic and placental inflammatory response. J Hypertens. 2023;41(1):150\u20138.","journal-title":"J Hypertens"},{"issue":"1","key":"978_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12877-022-03106-3","volume":"22","author":"DGJ McKechnie","year":"2022","unstructured":"McKechnie DGJ, Patel M, Papacosta AO, Lennon LT, Ellins EA, Halcox JPJ, et al. Associations between inflammation, coagulation, cardiac strain and injury, and subclinical vascular disease with frailty in older men: a cross-sectional study. BMC Geriatr. 2022;22(1):405.","journal-title":"BMC Geriatr"},{"key":"978_CR39","doi-asserted-by":"crossref","unstructured":"Plautz WE, Matthay ZA, Rollins-Raval MA, Raval JS, Kornblith LZ, Neal MD. Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness. Transfusion. 2020;60(Suppl 3):S158\u2013S166.","DOI":"10.1111\/trf.15667"},{"issue":"3","key":"978_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13586","volume":"231","author":"S Zhou","year":"2021","unstructured":"Zhou S, Guo J, Zhao L, Liao Y, Zhou Q, Cui Y, et al. ADAMTS13 inhibits oxidative stress and ameliorates progressive chronic kidney disease following ischaemia\/reperfusion injury. Acta Physiol (Oxf). 2021;231(3): e13586.","journal-title":"Acta Physiol (Oxf)"},{"issue":"1","key":"978_CR41","doi-asserted-by":"publisher","first-page":"14453","DOI":"10.1038\/s41598-019-51013-2","volume":"9","author":"S Ono","year":"2019","unstructured":"Ono S, Matsui H, Noda M, Kasuda S, Yada N, Yoshimoto K, et al. Functional regulation of von Willebrand factor ameliorates acute ischemia-reperfusion kidney injury in mice. Sci Rep. 2019;9(1):14453.","journal-title":"Sci Rep"},{"issue":"11","key":"978_CR42","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/nep.12893","volume":"22","author":"MG Kim","year":"2017","unstructured":"Kim MG, Lim SY, Ko YS, Lee HY, Jo SK, Cho WY. ADAMTS13-von Willebrand factor axis is involved in the pathophysiology of kidney ischaemia-reperfusion injury. Nephrology (Carlton). 2017;22(11):913\u201320.","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"978_CR43","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1161\/ATVBAHA.117.309539","volume":"37","author":"N Dhanesha","year":"2017","unstructured":"Dhanesha N, Doddapattar P, Chorawala MR, Nayak MK, Kokame K, Staber JM, et al. ADAMTS13 retards progression of diabetic nephropathy by inhibiting intrarenal thrombosis in mice. Arterioscler Thromb Vasc Biol. 2017;37(7):1332\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"978_CR44","doi-asserted-by":"publisher","first-page":"1081942","DOI":"10.3389\/fimmu.2022.1081942","volume":"13","author":"B Zhang","year":"2022","unstructured":"Zhang B, Xing G. Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation. Front Immunol. 2022;13:1081942.","journal-title":"Front Immunol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-00978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-00978-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-00978-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T15:01:36Z","timestamp":1748790096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-00978-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-00978-3","relation":{},"ISSN":["2192-4449"],"issn-type":[{"type":"electronic","value":"2192-4449"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent for publication of the case detail was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}